EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks

Andrew Blauvelt, Kim Papp, Mona Trivedi, Carolina Barragan, Vincent Chow, Daniel T Mytych, Paul Yamauchi, Jeff Crowley, Janet Franklin

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljae402 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Andrew Blauvelt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Medical Research Center, Portland, OR, USA. Hauptthemen laut MEDLINE: Psoriasis, Ustekinumab, Biosimilar Pharmaceuticals, Dermatologic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ABP 654 is a biosimilar to ustekinumab reference product (RP). ABP 654 has been shown to have an amino acid sequence identical to ustekinumab RP and they are similar in structure, purity and potency, as well as clinical pharmacokinetics and safety in healthy volunteers.

Objectives

To compare the efficacy, safety and immunogenicity of ABP 654 and ustekinumab RP in patients with moderate-to-severe plaque psoriasis in a randomized double-blinded active-controlled single-transition comparative clinical study (NCT04607980).

Methods

Patients were randomized 1 : 1 to receive ABP 654 or ustekinumab RP at a weight-based dose of 45 mg or 90 mg administered subcutaneously on day 1 (week 0), week 4 and week 16. At week 28, patients with a ≥ 75% improvement in Psoriasis Area and Severity Index (PASI) were re-randomized such that those initially randomized to ABP 654 continued to receive ABP 654 and those initially randomized to ustekinumab RP were re-randomized to either continue on ustekinumab RP or transition to ABP 654. The primary efficacy endpoint was percentage improvement in PASI from baseline to week 12. Secondary endpoints included additional efficacy measurements, as well as an assessment of adverse events and antidrug antibodies.

Results

At week 12, the observed mean (SD) percentage improvement in PASI from baseline was 81.9 (19.9) and 81.9 (19.6) for the ABP 654 and ustekinumab RP treatment groups, respectively. The point estimate of the mean difference in percentage PASI improvement from baseline to week 12 between the treatment groups was 0.14 with a two-sided 90% confidence interval (CI) of (–2.6 to 2.9), well within the prespecified similarity margin of (–10 to 10). In addition, throughout the study, secondary efficacy analyses and safety and immunogenicity profiles were similar across the treatment groups.

Conclusions

These results indicate that ABP 654 and ustekinumab RP are clinically similar in efficacy, safety and immunogenicity in patients with moderate-to-severe plaque psoriasis. Further, a single transition from ustekinumab RP to ABP 654 at week 28 had no impact on the efficacy, safety or immunogenicity results for the remainder of the 52-week study, supporting a conclusion of no clinically meaningful differences between ABP 654 and ustekinumab RP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisUstekinumabBiosimilar PharmaceuticalsDermatologic AgentsHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedTreatment OutcomeSeverity of Illness IndexInjections, SubcutaneousAged

Substanzen

UstekinumabBiosimilar PharmaceuticalsDermatologic Agents

Autor:innen und Institutionen

  • Oregon Medical Research Center, Portland, OR, USA.
  • Alliance Clinical Trials Probity Medical Research, Waterloo, ON, Canada.
  • Department of Medicine, Division of Dermatology, University of Toronto, Toronto, ON, Canada.
  • Amgen Inc., Thousand Oaks, CA, USA.
  • Dermatology Institute and Skin Care Center, Inc. Clinical Science Institute, Santa Monica, CA, USA.
  • Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA.

Förderung

  • Amgen Inc.

Zitieren

APA

Blauvelt, A., Papp, K., Trivedi, M., Barragan, C., Chow, V., Mytych, D. T., Yamauchi, P., Crowley, J., & Franklin, J. (2025). Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae402

Vancouver

Blauvelt A, Papp K, Trivedi M, Barragan C, Chow V, Mytych DT, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae402

BibTeX
@article{Blauvelt2025,
  author = {Blauvelt, Andrew and Papp, Kim and Trivedi, Mona and Barragan, Carolina and Chow, Vincent and Mytych, Daniel T and Yamauchi, Paul and Crowley, Jeff and Franklin, Janet},
  title = {Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljae402}
}
Kostenlos starten →